<div id="readability-page-1"><p>IQVIA (NYSE:IQV - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 12.550-12.850 for the period, compared to the consensus estimate of 12.480. The company issued revenue guidance of $17.2 billion-$17.4 billion, compared to the consensus revenue estimate of $17.1 billion.</p><h2>Wall Street Analyst Weigh In</h2><ul><li>Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors</li></ul><p>Several equities analysts have recently commented on IQV shares. Barclays  set a $230.00 price objective on IQVIA in a research report on Monday, December 15th. Hsbc Global Res raised IQVIA from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, October 9th. TD Cowen lifted their price target on shares of IQVIA from $215.00 to $245.00 and gave the stock a &#34;hold&#34; rating in a research note on Thursday, January 22nd. Evercore ISI boosted their price objective on shares of IQVIA from $220.00 to $240.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, October 8th. Finally, JPMorgan Chase &amp; Co. increased their target price on shares of IQVIA from $177.00 to $255.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued  a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $251.06.</p><p><b>View Our Latest Research Report on IQVIA</b></p><h2>IQVIA Trading Down 0.6%</h2><p>NYSE:IQV opened at $202.56 on Thursday. The firm has a market capitalization of $34.50 billion, a P/E ratio of 27.79, a P/E/G ratio of 2.07 and a beta of 1.37. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The company has a fifty day moving average of $229.85 and a 200 day moving average of $209.62. IQVIA has a 52 week low of $134.65 and a 52 week high of $247.04. </p><p>IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS.  On average, research analysts predict that  IQVIA will post 10.84 earnings per share for the current year. </p><h2>Hedge Funds Weigh In On IQVIA</h2><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC boosted its holdings in  IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company's stock valued at $1,163,000 after acquiring an additional 63 shares in the last quarter.  E Fund Management Co. Ltd. lifted its position in shares of  IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company's stock worth $331,000 after purchasing an additional 74 shares during the period.  Ancora Advisors LLC boosted its stake in shares of  IQVIA by 17.9% during the 3rd quarter. Ancora Advisors LLC now owns 521 shares of the medical research company's stock valued at $99,000 after purchasing an additional 79 shares in the last quarter.  Quadrant Capital Group LLC increased its position in shares of  IQVIA by 1.7% during the third quarter. Quadrant Capital Group LLC now owns 4,732 shares of the medical research company's stock valued at $899,000 after buying an additional 81 shares during the period.  Finally, Snowden Capital Advisors LLC raised its stake in  IQVIA by 5.3% in the second quarter. Snowden Capital Advisors LLC now owns 2,364 shares of the medical research company's stock worth $373,000 after buying an additional 120 shares in the last quarter. Institutional investors own  89.62% of the company's stock. </p><h2>IQVIA Company Profile</h2> (Get Free Report)<p>IQVIA <span>NYSE: IQV<span></span></span> is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.  </p><p>IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than IQVIA</li><li>The day the gold market broke</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Trump Planning to Use Public Law 63-43: Prepare Now</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlRVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlRVg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in IQVIA Right Now?</h2><p>Before you consider IQVIA, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.</p><p>While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

<p>IQVIA (NYSE:IQV) has updated its FY 2026 earnings guidance, projecting EPS between 12.550 and 12.850, surpassing the consensus estimate of 12.480. Revenue guidance is set at $17.2 billion to $17.4 billion, above the consensus of $17.1 billion. Analysts have varied price targets for IQVIA, with Barclays setting a target of $230.00 and JPMorgan raising it to $255.00. The stock currently has a consensus rating of "Moderate Buy" and a price target of $251.06. IQVIA's market cap is $34.50 billion, with a recent trading price of $202.56.</p>

IQVIA (NYSE:IQV) Updates FY 2026 Earnings Guidance